CAT-VHL - Exploring the role of Carbonic Anhydrase IX as diagnostic and Theranostic target in Von-Hippel Lindau disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515679-36-01

Acronym

CAT-VHL

Enrollment

Registered

2025-10-24

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Von-Hippel Lindau (VHL) Disease

Brief summary

To evaluate the efficacy of CAIX-PET for the detection of tumors in patients with VHL disease.

Detailed description

To evaluate the diagnostic accuracy of CAIX-PET in VHL -/- tumors diagnosed in the sporadic setting., To evaluate the diagnostic accuracy of CAIX-PET in VHL disease., To evaluate the safety of CAIX-PET.

Interventions

DRUGZr-DFO-girentuximab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
To evaluate the diagnostic accuracy of CAIX-PET in VHL -/- tumors diagnosed in the sporadic setting., To evaluate the diagnostic accuracy of CAIX-PET in VHL disease., To evaluate the safety of CAIX-PET.	—

Primary

Measure	Time frame
To evaluate the efficacy of CAIX-PET for the detection of tumors in patients with VHL disease.	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026